Mural im La Mission District San Francisco (Aufnahme Oncoletter)
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Für eine vollständige Ansicht aller 22 Abstract-Titel nutzen Sie bitte die Desktop-Version von Oncoletter
Link to Abstracts
Link to Posters: Sie müssen bei ASCO-GI eingeloggt sein und über eine aktuelle Registrierung verfügen, um auf die Poster dieser Sitzung zugreifen zu können. Hier können Sie die Registrierung erwerben.
- A phase 1b study of the OxPhos inhibitor ME-344 in combination with bevacizumab in refractory metastatic colorectal cancer.
- Combination of hSTC810 and capecitabine therapy in metastatic colorectal cancer with resistance or intolerance to oxaliplatin and irinotecan-based chemotherapy: A single arm, phase 1b/2, multicenter study.
- BXQ-350: A phase 1b/2 placebo controlled, double blinded study on the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma (mCRC).
- A randomized controlled trial of CAPEOX vs observation in patients with early-stage colorectal cancer with positive MRD after curative surgery (CAREME).
- Neoadjuvant anti-programmed death 1 (PD-1) therapy in patients (pts) with resectable mismatch repair–deficient (dMMR) locally advanced rectal cancer (LARC): EPOC2201.
- Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors.
- An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab plus bevacizumab for the treatment of patients with advanced colorectal carcinoma.
- Zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated MSS/MSI-low metastatic colorectal cancer (mCRC): The randomized phase 3 STELLAR-303 study.
- mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer (FROST trial): Study protocol for an open label, multicenter, randomized, phase II study.
- Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.
- A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.
- Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab for locally advanced MSS of middle and low rectal cancer (mRCAT): An open-label, single-arm, prospective, multicentre clinical trial.
- SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.
- Phase 2A trial of Ad5.F35-GUCY2C-PADRE vaccine for recurrence prevention in gastrointestinal (GI) adenocarcinomas post definitive surgery and adjuvant therapies.
- Alliance A022101: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur).
- No operation after short course radiotherapy followed by consolidation chemotherapy in locally advanced rectal cancer: The prospective, single arm NOAHS-ARC trial.
- Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01.
- A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update.
- AZUR-2, a phase III, open-label, randomized study of perioperative dostarlimab monotherapy vs standard of care in previously untreated patients with T4N0 or stage III dMMR/MSI-H resectable colon cancer.
- NSABP C-14/Exact Sciences 16-002: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease.
- MRD assay to evaluate recurrence and response via a tumor informed assessment: MARIA-Colorectal Cancer Observational trial.
- NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA).
Presenter: Patrick M Boland, MD | Rutgers Cancer Institute of New Jersey
TPS222 A phase 1b study of the OxPhos inhibitor ME-344 in combination with bevacizumab in refractory metastatic colorectal cancer.
Für Hintergrund und Methoden siehe Abstract
Presenter: Soohyeon Lee, MD, PhD | Korea University Anam Hospital
Presenter: Reema Anil Patel, MD | University of Kentucky
TPS224 BXQ-350: A phase 1b/2 placebo controlled, double blinded study on the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma (mCRC).
Für Hintergrund und Methoden siehe Abstract
Presenter: Ke-Feng Ding, MD, PhD | Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, Zhejiang
TPS225 A randomized controlled trial of CAPEOX vs observation in patients with early-stage colorectal cancer with positive MRD after curative surgery (CAREME).
Für Hintergrund und Methoden siehe Abstract
Presenter: Hideaki Bando, MD, PhD | Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East
TPS226 Neoadjuvant anti-programmed death 1 (PD-1) therapy in patients (pts) with resectable mismatch repair–deficient (dMMR) locally advanced rectal cancer (LARC): EPOC2201.
Für Hintergrund und Methoden siehe Abstract
Presenter: Ronan Joseph Kelly, MD, MBA | Charles A. Sammons Cancer Center, Baylor University Medical Center at Dallas
TPS227 Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors.
Für Hintergrund und Methoden siehe Abstract
Presenter: Heinz-Josef Lenz, MD | Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California
TPS228 An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab plus bevacizumab for the treatment of patients with advanced colorectal carcinoma.
Für Hintergrund und Methoden siehe Abstract
Presenter: Anwaar Saeed, MD | University of Pittsburgh Medical Center
TPS229 Zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated MSS/MSI-low metastatic colorectal cancer (mCRC): The randomized phase 3 STELLAR-303 study.
Für Hintergrund und Methoden siehe Abstract
Presenter: Kyung-ha Lee | Department of Surgery, Chungnam National University Hospital, Chungnam National University College of Medicine
TPS230 mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer (FROST trial): Study protocol for an open label, multicenter, randomized, phase II study.
Für Hintergrund und Methoden siehe Abstract
Presenter: Michael J. Overman, MD | The University of Texas MD Anderson Cancer Center
TPS231 Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.
Für Hintergrund und Methoden siehe Abstract
Presenter: Carlos Rojas, MD | Centro de Investigacion Clinica, Bradford Hill
TPS232 A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.
Für Hintergrund und Methoden siehe Abstract
Presenter: Zhangfa Song, PhD,MD | Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
TPS233 Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab for locally advanced MSS of middle and low rectal cancer (mRCAT): An open-label, single-arm, prospective, multicentre clinical trial.
Für Hintergrund und Methoden siehe Abstract
Presenter: Van K. Morris, MD | Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
TPS234 SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.
Für Hintergrund und Methoden siehe Abstract
Presenter: Babar Bashir, MD, MS, FACP, MSc | Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital
TPS235 Phase 2A trial of Ad5.F35-GUCY2C-PADRE vaccine for recurrence prevention in gastrointestinal (GI) adenocarcinomas post definitive surgery and adjuvant therapies.
Für Hintergrund und Methoden siehe Abstract
Presenter: Kathryn Hitchcock, MD, PhD | University of Florida/UF Health Cancer Center
TPS236 Alliance A022101: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur).
Für Hintergrund und Methoden siehe Abstract
Presenter: Felipe Fernando Quezada, MD | Complejo Asistencial Doctor Sotero del Rio
TPS237 No operation after short course radiotherapy followed by consolidation chemotherapy in locally advanced rectal cancer: The prospective, single arm NOAHS-ARC trial.
Für Hintergrund und Methoden siehe Abstract
Presenter: Ibrahim Halil Sahin, MD | University of Pittsburgh Medical Center
TPS238 Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01.
Für Hintergrund und Methoden siehe Abstract
Presenter: Neil Howard Segal, MD, PhD | Department of Medicine, Memorial Sloan Kettering Cancer Center
TPS239 A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update.
Für Hintergrund und Methoden siehe Abstract
Presenter: Naureen Starling, MD, MBBS, FRCP, BSc | The Royal Marsden NHS Foundation Trust
TPS240 AZUR-2, a phase III, open-label, randomized study of perioperative dostarlimab monotherapy vs standard of care in previously untreated patients with T4N0 or stage III dMMR/MSI-H resectable colon cancer.
Für Hintergrund und Methoden siehe Abstract
Presenter: Mohamed E. Salem, MD, FASCO | Levine Cancer Institute
TPS241 NSABP C-14/Exact Sciences 16-002: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease.
Für Hintergrund und Methoden siehe Abstract
Presenter: Edward D. Esplin, MD, PhD, FACP, FACMG | Invitae
TPS242 MRD assay to evaluate recurrence and response via a tumor informed assessment: MARIA-Colorectal Cancer Observational trial.
Für Hintergrund und Methoden siehe Abstract
Presenter: Christopher Hanyoung Lieu, MD, FASCO | University of Colorado Cancer Center
TPS243 NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA).
Für Hintergrund und Methoden siehe Abstract
Copyright 2024. All Rights Reserved.